Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging
1 other identifier
observational
100
1 country
1
Brief Summary
Chest pain and myocardial ischemia are prevailing features in patients with hypertrophic cardiomyopathy (HCM). Recently introduced single-photon emission computed tomography (SPECT) cameras with solid-state cadmium-zinc-telluride (CZT) detectors have been shown to decrease imaging time and improved the imaging quality of gated myocardial perfusion imaging (MPI). The investigators also correlate the MPI parameters with echocardiographic parameters. This study is to examine the spatial distribution of stress perfusion abnormalities and tissue injury in patients with HCM using a CZT SPECT camera.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 8, 2017
CompletedFirst Submitted
Initial submission to the registry
May 10, 2017
CompletedFirst Posted
Study publicly available on registry
May 12, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2018
CompletedMay 16, 2017
May 1, 2017
4 months
May 10, 2017
May 15, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
MPI results
including perfusion abnormalities, and ejection fraction phase analysis results
January 2013 and October 2016.
Interventions
dipyridamole-stressed MPI scan using thallium-201
Eligibility Criteria
HCM patients with patent coronary artery who underwent MPI
You may qualify if:
- clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016.
You may not qualify if:
- patient with prior myocardial ischemia, conduction abnormality, valvular disease or other cardiomyopathy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Far Eastern Memorial Hospital
New Taipei City, 220, Taiwan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yen-Wen Wu, MD, PhD
Far Eastern Memorial Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident Physician, department of nuclear medicine
Study Record Dates
First Submitted
May 10, 2017
First Posted
May 12, 2017
Study Start
May 8, 2017
Primary Completion
August 31, 2017
Study Completion
June 30, 2018
Last Updated
May 16, 2017
Record last verified: 2017-05